Kevin P. Bliden and Rahul Chaudhary contributed equally to the manuscript.
We wish to acknowledge our research coordinators, Tania Gesheff, Kiran Kalra, and Cescelle Barbour for their contributions to the study and Ms. Abby Jones for her technical assistance.
This study was funded by Coramed Technologies.
Paul Gurbel reports serving as a consultant for Daiichi Sankyo/Lilly, Bayer, AstraZeneca, Accumetrics, Merck, Medtronic, Janssen, CSL, and Haemonetics; receiving grants from the National Institutes of Health, Daiichi Sankyo, Lilly, CSL, AstraZeneca, Haemetics, Harvard Clinical Research Institute, and Duke Clinical Research Institute; receiving payment for lectures, including service on speakers' bureaus, from Lilly, Daiichi Sankyo, and Merck; receiving payment for development of educational presentations from Merck, the Discovery Channel, and Pri-Med; Dr. Gurbel is holding stock or stock options in Merck, Medtronic, and Pfizer; and holding patents in the area of personalized antiplatelet therapy and interventional cardiology. Ms. Muresan, Mr. Lopez-Espina, Ms. Cohen and Mr. Raviv are employees at Coramed Technologies. Mr. Doubleday is an employee at Haemonetics Corporation. Other authors report no disclosures.